 |
인쇄하기
취소
|
Bukwang receives first royalty over Levovir
Bukwang said it has received a first royalty of US$31,000 from Eisai Co., for the marketing of Levovir capsule (clevudine) in the Philippines.
Levovir has been prescribed in such country after successful registration from January.
Levovir is the first domestically developed treatment for the disease and the 11th original Korean drug to be formally certified by the government.
Bukwan...
Levovir has been prescribed in such country after successful registration from January.
Levovir is the first domestically developed treatment for the disease and the 11th original Korean drug to be formally certified by the government.
Bukwan...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.